First let me state I am deeply invested in Innovation Pharmaceuticals and want Brilacidin to be proven effective as a broad-spectrum antiviral and specifically effective versus SARS-CoV-2. My comment is only intended to express my opinion that results are not pre-ordained nor will they be obvious to practitioners in the clinical setting.

Patients get better. Simple as that. Remdesivir or not, Brilacidin + SOC or not, most patients get better. If the Brilacidin trial is recruiting 1-3 patients per site per week and most patients recover it will be difficult to recognize, even, a significant difference in progression toward wellness on a site by site anecdotal basis. The entire body of trial data will have to be evaluated before a difference in treatment outcomes and validation of Brilacidin will be recognized.